Logos Global Management LP
CIK 1792126 · last filed 2021-06-22
Logos Global Management LP is a corporate insider who has filed 3 SEC Form 4 insider transactions across 3 companies since 2020. The most recent filing, for VERV, was dated Jun 22, 2021. Across all open-market trades the lifetime net is +$22.3M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $23.6M across reported positions. The firm reports its address in San Francisco, CA. 2 SEC filings were submitted jointly with Cerecor Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
DYN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
BLDG C, SUITE C3-350
SAN FRANCISCO, CA 94129
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Verve Therapeutics, Inc. (VERV) Delisted | 10%+ Owner | 813,265 | $11.13 | $9.05M | $7.03M | 1 | 2021-06-22 |
| Eledon Pharmaceuticals, Inc. (NVUS) Delisted | 10%+ Owner | 150,000 | — | — | $2.00M | 1 | 2020-11-06 |
| DYN | 10%+ Owner | 1,504,392 | $15.72 | $23.65M | $13.30M | 1 | 2020-09-23 |
Recent Filings
3 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-06-22 | Verve Therapeutics, Inc. (VERV) Delisted | Mixed | +813,265 | $7.03M | EDGAR |
| 2020-11-06 | Eledon Pharmaceuticals, Inc. (NVUS) Delisted | Mixed | +79,071 | $2.00M | EDGAR |
| 2020-09-23 | DYN | Mixed | +1,504,392 | $13.30M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.